Volume 16, Number 5—May 2010
Letter
Cross-Reactive Antibodies to Pandemic (H1N1) 2009 Virus, Singapore
Table
Cross-reactive antibody titers to pandemic (H1N1) 2009 and seasonal influenza viruses for 50 persons, Singapore, May–October 2009*
Patient age, y/sex | Laboratory 1 (Singapore General Hospital) |
Laboratory 2 (WHO, Melbourne)+ |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
A/Auckland/1/2009 |
A/Brisbane/59/2007 |
A/Auckland/1/2009 |
A/Brisbane/59/2007 |
|||||||
HI† | MN | HI† | MN | HI‡ | HI† | HI‡ | ||||
45/F | <10 | <10 | <10 | <10 | <10 | <10 | <10 | |||
52/F | <10 | 10 | 10 | 10 | <10 | 10 | <10 | |||
52/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
52/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
53/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
53/F | <10 | <10 | 20 | 40 | <10 | <10 | 40 | |||
53/F | <10 | <10 | 160 | 80 | <10 | <10 | 160 | |||
53/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
53/F | <10 | <10 | 160 | 320 | <10 | <10 | 160 | |||
53/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
54/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
54/M | 10 | <10 | 10 | <10 | <10 | 20 | <10 | |||
55/F | <10 | <10 | 10 | <10 | <10 | 10 | <10 | |||
55/F | <10 | <10 | 160 | 40 | <10 | <10 | 160 | |||
55/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
56/F | <10 | <10 | 20 | 10 | <10 | <10 | 10 | |||
56/F | <10 | <10 | 80 | 80 | <10 | 20 | 40 | |||
56/F | <10 | 10 | 10 | 40 | <10 | <10 | 10 | |||
56/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
57/M | 10 | 20 | 40 | 40 | 20 | 20 | <10 | |||
58/M | <10 | <10 | 20 | 20 | <10 | 10 | 20 | |||
58/F | <10 | <10 | 40 | 20 | <10 | <10 | 80 | |||
59/M | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
59/M | <10 | <10 | 20 | 20 | 20 | 20 | 10 | |||
59/F | <10 | <10 | 40 | 40 | <10 | <10 | 40 | |||
60/M | <10 | <10 | 80 | 40 | <10 | <10 | 80 | |||
60/M | <10 | <10 | 20 | 10 | <10 | <10 | 20 | |||
60/F | 10 | <10 | 10 | <10 | NR | <10 | <10 | |||
61/F | 10 | <10 | 10 | <10 | <10 | 10 | <10 | |||
61/M | 10 | <10 | 160 | 160 | <10 | <10 | 320 | |||
61/M | <10 | <10 | <10 | <10 | <10 | <10 | <10 | |||
61/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
62/F | <10 | 20 | 10 | 20 | NR | NR | NR | |||
62/F | 10 | 10 | 80 | 20 | <10 | <10 | 40 | |||
62/F | <10 | <10 | 20 | 10 | <10 | 20 | 40 | |||
62/F | <10 | <10 | 80 | 40 | <10 | <10 | 80 | |||
63/M | <10 | <10 | 80 | 40 | <10 | <10 | 80 | |||
63/F | <10 | <10 | 10 | <10 | <10 | <10 | <10 | |||
63/M | <10 | <10 | 40 | 20 | <10 | <10 | 20 | |||
63/M | <10 | <10 | 40 | 80 | <10 | <10 | 20 | |||
64/F | 10 | <10 | 20 | 10 | <10 | 10 | 10 | |||
65/F | 10 | <10 | 10 | <10 | <10 | 20 | <10 | |||
66/M | <10 | <10 | <10 | <10 | <10 | <10 | <10 | |||
68/M | <10 | <10 | 40 | 80 | <10 | <10 | 40 | |||
71/F | 10 | 10 | 10 | 20 | <10 | <10 | <10 | |||
72/F | <10 | 20 | 10 | 20 | 10 | 10 | <10 | |||
75/M | <10 | <10 | 10 | 10 | <10 | 20 | <10 | |||
76/M | <10 | <10 | 40 | 20 | <10 | <10 | 40 | |||
78/F | <10 | 10 | 10 | 20 | <10 | <10 | <10 | |||
82/F | 10 | 10 | 20 | 10 | <10 | 20 | <10 |
*WHO, World Health Organization; HI, hemagglutination inhibition; MN, microneutralization; NR, no results (because of insufficient serum).
†Tested with guinea pig erythrocytes.
‡Tested with turkey erythrocytes.